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to purging activity, such that high cellularity (10e8 cells/ml) results
in a signiﬁcant loss (65%) of T and B cells with only 1 hr co-
incubation, raising to 85-90% at a 6 hr co-incubation. Co-incuba-
tion at a log lower cellularity results in a 20-30% T-cell loss.
ADCC is the primary purging mechanism; however, serum is
required to retain cellular viability as is DNAse to reduce cellular
clumping. Co-incubation temperature has little effect on purging,
although cellular viability is higher at 4C compared to 37C. T, B
and NK cells are sensitive to Alemtuzumab ADCC. DCs have a
lower sensitivity and there is a differential sensitivity of DC subsets
to alemtuzumab-mediated ADCC, such that CD123 DCs have a
lower sensitivity as compared to the CD11c DCs. Further, im-
mature myeloid suppressor cells (IMSCs) that are Lin-DR-
CD11b or Lin-DR-CD14-CD11b cells are refractory to alemtu-
zumab toxicity. This novel observation is of interest as IMSCs can
induce T cell tolerance and thus have the potential to control
GVHD. Critically, alemtuzumab purging of a hematopoietic stem
cell products has no effect on CD34 cell numbers and their
(CFU-c) as assessed in vitro.
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COMPARISON OF CELL DOSE AND OUTCOME FOR CORD BLOOD
TRANSPLANTATION (CBT) SOURCED FROM PLASMA DEPLETED (PD)
VERSUS RED CELL DEPLETED (RD) CORD BLOOD INVENTORIES
Wang, B.1, Tsukahara, E.1, Wu, T.1, Chow, T.1, Lin, A.2,
Gjertson, D.3, Petz, L.1, Chow, R.1,2,4 1StemCyte International Cord
Blood Center, Arcadia, CA; 2StemCyte Taiwan National Cord Blood
Center, Linkou, Taiwan; 3UCLA School of Public Health, Los Angeles,
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To discern whether cord blood processing inﬂuences cord blood
bank (CBB) inventory cell dose and CBT outcome, we (1) per-
formed a large scale cell dose comparison of the NMDP CBBs that
practice red cell depletion (RD) versus plasma depletion (PD), (2)
performed an analysis comparing RD CBT results from an Insti-
tute of Medicine (IOM) study to audited outcome from a PD cord
blood (CB) inventory, and (3) searched the literature for outcome
of CBBs that practice PD and RD processing. Two of the CBBs in
the NMDP network practice PD processing (n10,912 CB)
whereas all others practice RD (n38,819 CB). PD processing
results in less than 1% cell loss in the discarded fraction (excluding
testing and archival samples), and various studies have reported
different recovery rates for RD; however, no data exist for a
rigorous comparison of actual inventories. Using data from
NMDP’s Cord Blood Bank Performance Report (6/30/06), the
percentage of high cell dose units among the two types of CBBs
were compared. Table 1A shows the proportion of CB with high
TNC counts was signiﬁcantly higher for PD CBU at all three
levels (p 0.0001; test for difference in proportions). To our
knowledge, this is the largest cell dose comparison of cord blood
banks.
The IOM conducted a study that analyzed the outcome of 3 large
CB inventories in order to ﬁnd determinants of engraftment and
patient survival (Gibbons 2005). The IOM study used RD CB. All
205 patients transplanted with PD CB through 5/06 with survival
and/or engraftment data were divided into three groups - alive,
dead, and engraftment failure - which were then compared to the
755 transplants from the IOM study using identical methodologies
(aliveengrafted & alive, deadengrafted & dead, and engraft-
ment failurenever engrafted). Table 1B summarizes the propor-
tion of patients in each category and chi-square test of homoge-
neity yielded a p-value of 0.002, suggesting that the PD CBT had
a signiﬁcantly higher proportion of survivors and lower proportion
of engraftment failures.
Various cord blood bank studies from the literature were also
summarized, which showed that transplants using PD CB may
have higher cell doses than those using RD CB. Moreover, various
RD CB inventories appeared to have similar outcome, which may
be different from transplants using PD CB inventories though
patient and disease proﬁles appear to match.
Cell Dose & Outcome Comparison Between PD & RD CB
Inventories
Table 1A NMDP PD CBB NMDP RD CBB
Test
for
Difference
CBU with
TNC
# & % of PD CB # & % of RD CB in Proportions
>125 107 3,772 (35%) 8,172 (21%) p < 0.0001
>150 107 2,157 (20%) 3,871 (10%) p < 0.0001
>200 107 703 (6%) 822 (2%) p < 0.0001
Table 1B # & % Alive # & % Dead
# & % Engraftment
Failure
PD CB 116(56.6%) 47(22.9%) 42(20.5%)
IOM CB 323(42.8%) 214(28.3%) 218(28.9%)
HEMATOPOIESIS/MESENCHYMAL CELLS
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TRANSPLANTATION OF VASCULAR ENDOTHELIAL CELLS MEDIATES
THE HEMATOPOIETIC RECOVERY AND SURVIVAL OF IRRADIATED MICE
Muramoto, G.G.1, Himburg, H.1, Salter, A.1, Meadows, S.1, Chen, B.1,
Rickman, D.1, Chao, N.J.1, Chute, J.P.1 1Duke University Medical
Center, Durham, NC.
During embryogenesis, Flk-1 endothelial precursors contrib-
ute critically to the deﬁnitive onset of hematopoiesis. Adult sources
of endothelial cells have also been shown to support the expansion
of hematopoietic stem cells in vitro. However, the in vivo contri-
bution of vascular endothelial cells to adult hematopoiesis has been
less well characterized. In this study, we sought to determine
whether transplantation of primary endothelial cells could enhance
the hematopoietic recovery and survival of lethally irradiated mice.
C57BL/6J mice were given sublethal (700 cGy) or lethal (1050
cGy) irradiation and subsequently transplanted with murine brain-
derived ECs (MBECs) or fetal blood-derived ECs (FBECs) for 5
days. Mice transplanted with MBECs alone demonstrated acceler-
ated BM cellular recovery, radioprotection of BM c-kitsca-1-lin-
progenitors and enhanced regeneration of c-kitsca-1lin-(KSL)
stem/progenitor cells following irradiation compared to controls.
MBEC transplantation also facilitated the recovery of circulating
white blood cells and platelet counts following radiation exposure.
Remarkably, 57% of mice transplanted with MBECs survived
long-term (60 days) following 1050 cGy irradiation, which was
100% lethal in control mice. Irradiated mice that were trans-
planted with FBECs also showed signiﬁcantly increased survival,
although these animals did not survive long-term. Conversely,
transplantation with mesenchymal stem cells (MSCs) had no im-
pact on the survival of irradiated mice, suggesting that an endo-
thelial cell-speciﬁc activity accounted for the observed effects.
These data suggest that vascular endothelial cells can mediate
hematopoietic recovery following myeloablative injury and that
transplantation of endothelial cells alone can improve the survival
of lethally irradiated animals.
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MESENCHYMAL STEM CELLS ARE EFFECTIVE AT PREVENTING BUT
NOT AT TREATING GVJD
Tisato, V.1, Naresh, K.2, Navarrete, C.3, Dazzi, F.1 1Departmento of
Haematology - Imperial College, London, United Kingdom; 2Depart-
ment of Pathology - Imperial College, London, United Kingdom; 3Na-
tional Blood Service, London, United Kingdom.
Mesenchymal stem cells (MSC) are progenitor cells of stromal
origin which can differentiate into multiple lineages. MSC also
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